Advertisement
Advertisement

OVID

OVID logo

Ovid Therapeutics Inc. Common Stock

2.80
USD
Sponsored
-0.07
-2.44%
May 13, 15:39 UTC -4
Closed
exchange

Pre-Market

2.75

-0.05
-1.96%

Ovid Therapeutics Inc. Common Stock Profile

About

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.

Info & Links

CEO

Margaret Alexander

Headquarters

441 Ninth Avenue, 14th Floor
New York, NY 10001, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.ovidrx.com

Auditor

KPMG LLP

Share holders

18

Employees

23

Ovid Therapeutics Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

512.33M

Enterprise Value

512.59M

Enterprise Value/EBITDA(ttm)

-12.16

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

52.37

Price to Book(mrq)

2.87

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-240.11%

Profit Margin(ttm)

-3953.14%

Return on Equity(ttm)

-23.98%

Return on Invested Capital(ttm)

-35.52%

Return on Assets(ttm)

-18.63%

Income Statement

Revenue(ttm)

7.25M

Revenue Per Share(ttm)

0.05

Gross Profit(ttm)

7.25M

EBITDA(ttm)3

-42.17M

Net Income Available to Common(ttm)

-17.41M

Diluted EPS(ttm)

-0.31

Share Statistics

Beta (5Y Monthly)

-0.03

52-Week Change

879.02%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

131.87M

Dividend Yield

0.00%

Float4

114.60M

% Held by Insiders

13.10%

% Held by Institutions

72.24%

Balance Sheet

Total Cash(mrq)

69.64M

Total Cash Per Share(mrq)

0.53

Total Debt(mrq)

13.42M

Total Debt/Equity(mrq)

10.27%

Current Ratio(mrq)

8.97%

Quick Ratio(mrq)

8.97%

Book Value Per Share(mrq)

1.00

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.52

Free Cash Flow(ytd)

-38.33M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement